Phase 2 Chronic Fatigue Syndrome Trial, Recruiting NCT06366724 Sponsor: Brigham and Women's Hospital Condition: Chronic Fatigue Syndrome
Back to Chronic Fatigue Syndrome

Phase 2 Chronic Fatigue Syndrome Trial, Recruiting

NCT06366724
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) meeting specific recognized diagnostic criteria, including symptoms that get worse when standing or sitting upright.
  • You are between 18 and 70 years old.
  • Your symptoms started before December 2023.
  • If you are a woman who could become pregnant, you agree to use contraception throughout the study.
  • You are willing and able to follow all study requirements for the full length of the trial.
  • Your body weight falls within a healthy range for your height (BMI between 17 and 40).
  • You agree not to join any other clinical trial that involves a treatment or intervention while in this study.
  • You have a working smartphone that can run a specific mobile app called DANA Brain Vital.

Who may not be able to join:

  • You are pregnant, trying to become pregnant, or currently breastfeeding.
  • You have used opioid (strong painkiller) medications in the last 30 days.
  • You test positive for opioids in a urine test.
  • You have a history of misusing alcohol, opioids, or other substances.
  • You have taken part in another clinical trial involving a treatment in the last 30 days, or plan to during this study.
  • You have a known allergy to the study medication or its ingredients.
  • The study doctor believes you have a condition that makes it unsafe or unsuitable for you to participate (confirm with trial site).
  • You have Type 1 or Type 2 diabetes.
  • You have been admitted to a hospital in the last 30 days, or have a planned hospital stay or surgery during the study period that may affect results.
  • You have a significant lung condition (such as COPD, cystic fibrosis, severe asthma, tuberculosis, pulmonary fibrosis, or lung cancer) or a significant heart condition.
  • You have an active cancer or have been recently treated for cancer.
  • You have started a new exercise routine within the last 4 weeks before joining the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: David Systrom, MD, Massachusetts General Hospital

Phone: 617-525-6797

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
10 September 2024
Est. completion
1 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Functional Capacity; Physiologic Response - Oxygen Uptake Efficiency Slope (OUES); Physiologic Response - Oxygen Utilization (VO2); Physiologic Response - Heart Rate Recovery (HRR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov